The establishment of EVISA is funded by the EU through
the Fifth Framework Programme (G7RT- CT- 2002- 05112).
Supporters of EVISA includes:
An orally administered third generation platinum compound with potential antineoplastic activity. Satraplatin
forms highly reactive, charged, platinum complexes which bind to
nucleophilic groups in DNA, inducing intrastrand and interstrand DNA
cross-links, as well as DNA-protein cross-links. These cross-links
result in cell growth inhibition and apoptosis.
The term "satraplatin" was found in the following pages: